Combination therapy: an upcoming paradigm to improve kidney and cardiovascular outcomes in chronic kidney disease
Overview
Paper Summary
This review summarizes the evidence supporting the use of multiple medications (combination therapy) to treat chronic kidney disease, particularly in people with diabetes. Recent advances have introduced several drug classes with complementary mechanisms for protecting the kidneys and cardiovascular system. These medications include SGLT2 inhibitors, GLP-1 receptor agonists, and the non-steroidal mineralocorticoid receptor antagonist finerenone.
Explain Like I'm Five
This review discusses using multiple medications together to treat chronic kidney disease, especially in people with diabetes. Combining drugs might better target the disease's different causes.
Possible Conflicts of Interest
The supplement containing this review was financially supported by Bayer AG, a pharmaceutical company that manufactures some of the medications discussed. Several authors also reported receiving research grants, consulting fees, and other support from various pharmaceutical companies.
Identified Limitations
Rating Explanation
This review provides a thorough overview of the rationale and evidence for using combination therapy in chronic kidney disease. The authors discuss the relevant pathophysiology, summarize key clinical trials, and address practical implications. Although the narrative review format carries an inherent risk of bias, the authors transparently disclose potential conflicts of interest related to industry funding and support.
Good to know
This is the Starter analysis. Paperzilla Pro fact-checks every citation, researches author backgrounds and funding sources, and uses advanced AI reasoning for more thorough insights.
Explore Pro →